Skip to main content
. 2020 Apr 17;87(3):E281–E288. doi: 10.1093/neuros/nyaa095

FIGURE.

FIGURE.

Immune checkpoint pathways. A, CTLA4 on the surface of T cells binds to CD80/CD86 on antigen-presenting cells to dampen early T-cell activation. B, PD1 on activated T cells binds to PDL1 on tumor cells or target organs to dampen the effector phase of T-cell activation. FDA-approved checkpoint blockade agents are shown in boxes. MHC: major histocompatibility complex, TCR: T-cell receptor, CD28: cluster of differentiation 28, CTLA4: cytotoxic T-lymphocyte-associated protein 4, CD80/CD86: cluster of differentiation 80/86, PD1: programmed cell death protein 1, PDL1: programmed death-ligand 1.